Dyslipidemia Management
Definition
Dyslipidemias are disorders of blood lipid levels encompassing elevated LDL-C (and total cholesterol), hypertriglyceridemia, and elevated Lp(a). Management targets atherogenic lipoprotein reduction to lower ASCVD risk and, for severe hypertriglyceridemia, prevention of acute pancreatitis. The 2026 ACC/AHA guideline represents the most current comprehensive framework, expanding focus beyond LDL-C to non-HDL-C, ApoB, and Lp(a) as therapeutic targets.
Key Concepts
Screening
- Adults: lipid profile from age 19, every ≥5 years; more frequently with additional ASCVD risk factors sources/lipid-aha-2026 (very high)
- Children: universal screen ages 9–11; cascade screening from age ≥2 if family history of premature ASCVD or FH
- Martin/Hopkins or Sampson/NIH equations are preferred over Friedewald for LDL-C estimation (COR 1) — superior accuracy at low LDL-C and elevated TG levels
- Non-HDL-C (= TC – HDL-C) should be routinely reported; better predictor of ASCVD than LDL-C, correlates strongly with ApoB sources/lipid-aha-2026 (very high)
- Advanced lipoprotein testing (NMR, gel electrophoresis): NOT recommended for routine use (COR 3) sources/lipid-aha-2026 (very high)
ApoB — When and Why to Measure
- ApoB directly counts atherogenic particle number (1 ApoB per LDL, VLDL, Lp(a) particle) vs LDL-C which reflects cholesterol mass only sources/lipid-aha-2026 (very high)
- Discordance between LDL-C at goal but ApoB elevated = persistent atherogenic risk; most common in CKM syndrome, elevated TG ≥150 mg/dL, diabetes
- COR 2a: measure ApoB in adults on LLT (especially ASCVD, CKM, diabetes, elevated TG) once LDL-C/non-HDL-C goals met
- ApoB unaffected by fasting status; standardized assay
- ApoB <80 mg/dL corresponds to LDL-C <70 mg/dL target; ApoB <65 mg/dL corresponds to LDL-C <55 mg/dL
Treatment Goals by Risk Category
| Setting |
LDL-C Goal |
Non-HDL-C Goal |
ApoB Goal |
| Very high risk ASCVD |
<55 mg/dL (1.4 mmol/L) |
<85 mg/dL (2.2 mmol/L) |
<65 mg/dL |
| ASCVD not very high risk |
<70 mg/dL (1.8 mmol/L) |
<100 mg/dL (2.6 mmol/L) |
<80 mg/dL |
| Primary prevention high risk (≥10%) |
<70 mg/dL |
<100 mg/dL |
<80 mg/dL |
| Primary prevention intermediate/borderline |
<100 mg/dL |
<130 mg/dL |
<100 mg/dL |
| Diabetes (40–75 y) |
<100 mg/dL |
<130 mg/dL |
— |
| CAC ≥1000 AU |
<55 mg/dL |
<85 mg/dL |
— |
Statin Therapy — Foundation of Treatment
- High-intensity statins (atorvastatin 40–80 mg, rosuvastatin 20–40 mg): ≥50% LDL-C reduction
- Moderate-intensity statins: 30–49% LDL-C reduction
- Statins are first-line for all major risk categories; CVOT evidence across primary and secondary prevention is extensive sources/lipid-aha-2026 (very high)
- Statin-associated diabetes risk: small but real in those with predisposing factors (BMI ≥30, fasting glucose ≥100, metabolic syndrome, HbA1c 6–6.4%); does NOT justify statin discontinuation — ASCVD benefit vastly outweighs sources/lipid-aha-2026 (very high)
Nonstatin LDL-C Lowering Agents
| Drug |
LDL-C Reduction |
Route |
Key Data |
| Ezetimibe |
18% mono; +25% with statin |
Oral daily |
IMPROVE-IT (secondary prevention benefit) |
| Evolocumab (PCSK9 mAb) |
45–64% |
SC every 2 weeks |
FOURIER |
| Alirocumab (PCSK9 mAb) |
45–64% |
SC every 2–4 weeks |
ODYSSEY OUTCOMES |
| Bempedoic acid (ACL inhibitor) |
21–24% mono; +17–18% with statin |
Oral daily |
CLEAR OUTCOMES |
| Inclisiran (siRNA PCSK9i) |
48–52% |
SC every 6 months (after initial doses) |
CVOTs ongoing |
| Bile acid sequestrants |
10–27% |
Oral |
Limited CVOT; GI side effects |
Hypertriglyceridemia Management
- Lifestyle first: low added sugar, reduced refined carbs, saturated fat, alcohol; weight loss 5–10%; ≥150 min/wk moderate aerobic exercise sources/lipid-aha-2026 (very high)
- TG 150–499 mg/dL: statins reduce TG 10–30%; prioritise ASCVD risk reduction
- TG 500–999 mg/dL: add fibrates (fenofibrate preferred over gemfibrozil — fewer DDI) or prescription omega-3 fatty acids to reduce pancreatitis risk
- TG ≥1000 mg/dL: very-low-fat diet (<10–15% calories from fat); eliminate alcohol and added sugar; fibrates or omega-3 fatty acids; refer to RDN (COR 1)
- FCS (familial chylomicronemia syndrome): olezarsen (apoC3 ASO, 80 mg monthly SC) — COR 1; reduced pancreatitis episodes in BALANCE trial
- Icosapent ethyl (IPE): COR 2b for adults ≥50 with ASCVD or diabetes + ≥1 risk factor + TG 150–499 mg/dL + LDL-C <100 mg/dL on statin (REDUCE-IT: 25% composite MACE reduction, but mineral oil placebo controversy); associated with increased AF and bleeding risk
- Fibrates and niacin: NO proven ASCVD event reduction when added to statin therapy
- Gemfibrozil: NEVER combine with statins (serious myopathy risk)
Dietary Supplements — Not Recommended
- Fish oil, red yeast rice, berberine, garlic, cinnamon, turmeric, plant sterols: no significant LDL-C reduction vs placebo (SPORT trial) sources/lipid-aha-2026 (very high)
- COR 3: No Benefit — common patient perception of safety over FDA-approved medications is misleading
Lifestyle Management
- Dietary pattern: emphasise fruits, vegetables, nuts, legumes, whole grains, fibre; replace saturated/trans fats with mono- and polyunsaturated fats (Mediterranean, DASH, vegan/vegetarian diets); clinical trial evidence shows replacing saturated fat (animal fats, tropical oils) with polyunsaturated fat reduces LDL-C concentrations — a causal CVD risk factor — and is associated with reduced CHD risk sources/diet-aha-2026 (very high)
- Fish oil supplements do NOT reduce CVD risk in otherwise healthy adults and may increase AF risk — important distinction from dietary fish (non-fried seafood), which is associated with lower CVD events and MI risk sources/diet-aha-2026 (very high). Note: icosapent ethyl (prescription-grade concentrated EPA, 4 g/day) carries a separate hypertriglyceridemia indication (COR 2b) but also carries AF risk — see hypertriglyceridemia section above
- Exercise: ≥150 min/wk moderate-to-vigorous aerobic + upper/lower body resistance exercise 2 d/wk
- Weight loss ≥5% associated with TG reduction ~4 mg/dL per kg lost; modest LDL-C reduction
- Healthy lifestyle halves ASCVD risk even in genetic predisposition (AHA Life's Essential 8)
Statin-Attributed Muscle Symptoms (SAMS)
- Bilateral symmetrical proximal myalgia/weakness within weeks of statin start; resolves within weeks of stopping
- Evaluate secondary causes before attributing to statin; CK measurement only for severe symptoms
- "Drucebo effect" (expectation-driven symptoms) is common
- Management escalation: reduce dose → alternate-day dosing → switch statin → add bempedoic acid/ezetimibe → PCSK9 mAb
- CoQ10 supplementation: NOT recommended (COR 3: No Benefit) sources/lipid-aha-2026 (very high)
Monitoring
- Lipid profile 4–12 weeks after initiation or dose adjustment; every 6–12 months thereafter (COR 1)
- Routine CK measurement: NOT recommended (COR 3) unless severe symptoms
- Routine hepatic transaminase monitoring: NOT recommended (COR 3); check only if symptoms of hepatotoxicity
Special Populations
- CKD Stage 3+: Treat as ASCVD equivalent; no benefit of initiating statin in dialysis patients (2 negative RCTs)
- HIV (40–75 y, stable ART): Pitavastatin COR 1 (REPRIEVE trial); pitavastatin preferred — minimal CYP3A4 DDI with antiretrovirals sources/lipid-aha-2026 (very high)
- Cancer survivors (life expectancy ≥2 y): Treat per standard guidelines; continue statins in active cancer unless DDI or life expectancy <1 y
- Pregnant women with TG ≥500 mg/dL: Fibrates (after first trimester) or prescription omega-3 fatty acids (COR 2a)
- Age >75: LLT can be considered; individualized decision balancing ASCVD risk vs competing comorbidities
CCD Secondary Prevention Lipid Management
- Very High Risk ASCVD Definition (2023 CCD Guideline, Table 10): Multiple major ASCVD events OR 1 major event + ≥2 high-risk conditions. Major events: recent ACS (≤12 mo), prior MI, ischaemic stroke, symptomatic PAD (ABI <0.85 or prior revascularisation/amputation). High-risk conditions: age ≥65, FH, prior CABG/PCI outside the major event, DM, HTN, CKD (eGFR 15–59), current smoking, LDL ≥100 on max statin+ezetimibe, history of CHF. (sources/CCS-AHA-2023, rating: very high)
- High-intensity statin COR 1/A: ≥50% LDL-C reduction target; generic formulations are cost-saving (high value); monitor lipids 4–12 weeks after initiation/dose change, then every 3–12 months. (sources/CCS-AHA-2023, rating: very high)
- Ezetimibe for very high risk + LDL ≥70 mg/dL on max statin — COR 2a/B-R: IMPROVE-IT 7% relative RRR; highest benefit in TRS2P ≥3 high-risk features (19% RRR, 6.3% ARR); generic ezetimibe is high value (<$50K/QALY). Add ezetimibe before PCSK9 mAb. (sources/CCS-AHA-2023, rating: very high)
- PCSK9 mAb for very high risk + LDL ≥70 or non-HDL ≥100 on max statin + ezetimibe — COR 2a/A: FOURIER (evolocumab) and ODYSSEY OUTCOMES (alirocumab): 15% MACE reduction each; uncertain economic value at current US prices (~$5,850/year; ICER ~$150K/QALY in most analyses). Bypass ezetimibe step only if ≥25% LDL reduction needed urgently. (sources/CCS-AHA-2023, rating: very high)
- Icosapent ethyl 4 g/day — COR 2b/B-R: CCD patients with LDL <100 + TG 150–499 mg/dL on statin — REDUCE-IT: 25% MACE RRR, 20% CV death reduction (mineral oil placebo controversy same as ACC/AHA 2026 position); incident AF higher; dietary omega-3 NOT a substitute. (sources/CCS-AHA-2023, rating: very high)
- Bempedoic acid / inclisiran — COR 2b: When ezetimibe and PCSK9 mAb are insufficient or not tolerated; LDL reduction 15–25% (bempedoic acid) and ~50% (inclisiran). Note: CLEAR Outcomes (bempedoic acid MACE benefit 13%) published after this guideline — may be upgraded in future revision. (sources/CCS-AHA-2023, rating: very high)
- Niacin, fenofibrate, dietary omega-3 supplements — COR 3 No Benefit: No CV event reduction on background statin (AIM-HIGH, HPS2-THRIVE, ACCORD-LIPID, PROMINENT, Cochrane omega-3 meta-analysis). Fenofibrate only for TG ≥500 to prevent pancreatitis. (sources/CCS-AHA-2023, rating: very high)
ACS-Specific LDL-C Management
- [2025 ACC/AHA ACS Guideline] ACS patients have substantially higher ASCVD event rates than stable CCD (1-year rates of CV death/MI/stroke estimated 10–15% after ACS hospitalization) — justifying more aggressive LDL-C lowering. (sources/ACS-AHA-2025, rating: very high)
- High-intensity statin immediately post-ACS: Class I/A; benefit appears early and is independent of baseline LDL-C; do NOT de-escalate if tolerated. (sources/ACS-AHA-2025, rating: very high)
- Add nonstatin if LDL-C ≥70 mg/dL on maximal statin: Class I/A. Options: ezetimibe (IMPROVE-IT: 6.4% relative MACE reduction vs statin alone, median 6 years), alirocumab (ODYSSEY OUTCOMES: 15% MACE reduction), evolocumab (FOURIER). (sources/ACS-AHA-2025, rating: very high)
- Add nonstatin if LDL-C 55–69 mg/dL on maximal statin: Class IIa/B-R. PCSK9 inhibitor secondary analyses from FOURIER/ODYSSEY support monotonic benefit with lower achieved LDL-C even well below 50 mg/dL. No neurocognitive or muscle safety concern at very low LDL-C. (sources/ACS-AHA-2025, rating: very high)
- Concurrent ezetimibe initiation with maximal statin: Class IIb/B-R — reasonable if LDL-C goal not achieved on statin alone. (sources/ACS-AHA-2025, rating: very high)
- Lipid reassessment: Fasting lipid panel 4–8 weeks after initiating/adjusting LLT post-ACS — Class I/C-LD. LDL-C decreases modestly beginning 24 hours after symptom onset; obtain lipid profile ASAP at presentation. (sources/ACS-AHA-2025, rating: very high)
- See entities/Acute-Coronary-Syndrome for full ACS secondary prevention context. (sources/ACS-AHA-2025, rating: very high)
ESC 2025 Additions and Revisions
- HIV primary prevention (COR I B, new ESC recommendation): statin therapy recommended for all PWH aged ≥40 y in primary prevention, irrespective of estimated CV risk and LDL-C levels (REPRIEVE: 35% MACE reduction with pitavastatin 4 mg; NNT 106 at 5 years) sources/lipid-esc-2025 (very high)
- Cancer/cardio-oncology (COR IIa B, new): statins should be considered in patients at high/very high risk of chemotherapy-related CV toxicity to reduce anthracycline-induced cardiac dysfunction (STOP-CA: atorvastatin 40 mg → 22% vs 9% LVEF decline; P=.002) sources/lipid-esc-2025 (very high)
- Bempedoic acid (COR I B for statin-intolerant; COR IIa C as add-on): added to ESC 2025 nonstatin options. CLEAR Outcomes: 13% MACE reduction (HR 0.87) in statin-intolerant patients. Adverse effects: hyperuricaemia/gout risk, raised liver enzymes, renal impairment sources/lipid-esc-2025 (very high)
- ACS — combination initiation (COR IIa B): high-intensity statin + ezetimibe should be considered at index ACS hospitalization in treatment-naïve patients not expected to reach LDL-C goal with statin alone ("strike early and strong" strategy) sources/lipid-esc-2025 (very high)
- Volanesorsen for FCS (COR IIa B): 300 mg/week SC; 77% TG reduction in FCS (mean baseline TG 2209 mg/dL); reduces pancreatitis risk. EMA-approved only (not FDA). Adverse effects: thrombocytopenia (requires monitoring), injection-site reactions 60% sources/lipid-esc-2025 (very high)
- Dietary supplements (COR III B): ESC 2025 explicitly recommends AGAINST dietary supplements or vitamins without documented safety and significant LDL-C-lowering efficacy. Consistent with ACC/AHA 2026 position sources/lipid-esc-2025 (very high)
Contradictions / Open Questions
- REDUCE-IT placebo controversy: Mineral oil placebo caused deleterious lipid/inflammatory changes in the control arm, possibly exaggerating IPE benefit; true benefit magnitude uncertain. No validation from STRENGTH trial (omega-3+DHA negative). ESC 2025 acknowledges discordance but still recommends ICE (2×2 g/day) COR IIa B; ACC/AHA 2026 gives only COR 2b. sources/lipid-aha-2026 sources/lipid-esc-2025 (both very high)
- Lp(a)-specific therapy: No definitive CVOT evidence yet for Lp(a)-lowering RNA therapies; phase 3 outcomes trials ongoing
- Statin use in pregnancy: FDA removed pregnancy as contraindication in 2024 (ACC/AHA 2026); ESC 2025 does not address this; statins should be avoided while lactating
- Threshold for LLT at age <30: 30-year risk estimates available but clinical trial evidence for treatment at this age is sparse
- FCS treatment: volanesorsen (ESC/EMA) vs olezarsen (ACC/AHA/FDA): ESC 2025 recommends volanesorsen (anti-ApoC-III ASO, EMA-approved, COR IIa B) for FCS; ACC/AHA 2026 recommends olezarsen (anti-ApoC-III ASO, FDA-approved, COR 1) for FCS. Both target ApoC-III but are different molecules with different regulatory approvals — region-specific formulary access will determine clinical use sources/lipid-esc-2025 sources/lipid-aha-2026 (both very high)
- IPE recommendation strength discordance: ACC/AHA 2026 gives icosapent ethyl COR 2b (noting REDUCE-IT placebo controversy); ESC 2025 gives COR IIa B. Class difference reflects different weighting of the mineral oil placebo controversy
Connections
Sources